LENSAR（LNSR）株式概要
商業段階の医療機器会社であるLENSAR, Inc.は、白内障の治療と、既存または手術によって誘発された角膜乱視の管理のためのレーザーシステムの設計、開発、マーケティングに重点を置き、米国システム、ヨーロッパ、アジア、韓国、そして国際的に活動している。 詳細
LNSR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LENSAR, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$5.72 |
| 52週高値 | US$13.47 |
| 52週安値 | US$5.06 |
| ベータ | 0.87 |
| 1ヶ月の変化 | -6.08% |
| 3ヶ月変化 | 2.51% |
| 1年変化 | -54.20% |
| 3年間の変化 | 51.32% |
| 5年間の変化 | -30.41% |
| IPOからの変化 | -36.44% |
最新ニュース
ナラティブの更新 • Jun 22
LNSR: Recent Upgrade And Margin Outlook Will Drive Repricing Potential
Analysts have maintained their $8.50 price target on LENSAR, citing a modestly lower discount rate and slightly adjusted long term margin and P/E assumptions following a recent upgrade in Street research coverage. What's in the News On April 10, 2026, LENSAR reported that Chief Financial Officer Thomas R.ナラティブの更新 • Jun 03
LNSR: Post Deal Selloff Will Set Up Margin Led Repricing Potential
Analysts have lifted their price target on LENSAR to $10, citing stronger profit margin expectations, a lower assumed discount rate, and a reduced future P/E, even as projected revenue growth is now more conservative. Analyst Commentary Bullish Takeaways Bullish analysts highlight the $10 price target as reflecting confidence that LENSAR's expected profit margins can support a higher valuation multiple than previously assumed.ナラティブの更新 • May 04
LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.Recent updates
ナラティブの更新 • Jun 22
LNSR: Recent Upgrade And Margin Outlook Will Drive Repricing Potential
Analysts have maintained their $8.50 price target on LENSAR, citing a modestly lower discount rate and slightly adjusted long term margin and P/E assumptions following a recent upgrade in Street research coverage. What's in the News On April 10, 2026, LENSAR reported that Chief Financial Officer Thomas R.ナラティブの更新 • Jun 03
LNSR: Post Deal Selloff Will Set Up Margin Led Repricing Potential
Analysts have lifted their price target on LENSAR to $10, citing stronger profit margin expectations, a lower assumed discount rate, and a reduced future P/E, even as projected revenue growth is now more conservative. Analyst Commentary Bullish Takeaways Bullish analysts highlight the $10 price target as reflecting confidence that LENSAR's expected profit margins can support a higher valuation multiple than previously assumed.ナラティブの更新 • May 04
LNSR: Buy Thesis Will Rebuild Around Post Deal Selloff And Adoption Reacceleration
Analysts have nudged their price target on LENSAR stock to $8.50, with recent upgrades to Buy and renewed confidence around the ALLY System adoption story cited as key reasons for the updated view. Analyst Commentary Recent research has focused on how the ALLY System adoption story and the fallout from the halted Alcon acquisition are shaping expectations for LENSAR’s execution and valuation.ナラティブの更新 • Apr 19
LNSR: Buy Thesis Rebuilds Around Post Deal Selloff And Adoption Reacceleration
Analysts have raised their price targets on LENSAR shares to $10, citing renewed optimism around ALLY System adoption and viewing the post acquisition setback selloff as a second chance for investors. Analyst Commentary Bullish Takeaways Bullish analysts point to a $10 price target as a simple yardstick for how they frame upside potential if ALLY System adoption trends seen before the Alcon deal announcement can be re established.
新しいナラティブ • Apr 17
Cataract Procedure Bundling Will Pressure Margins Yet Recurring Revenue Should Support Gradual Recovery
Catalysts About LENSAR LENSAR develops and commercializes robotic femtosecond laser systems for cataract surgery, with a focus on its ALLY Robotic Laser Cataract System. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Apr 03
LNSR: Buy Rating Resets Around Post Deal Selloff And Execution Rebuild
Analysts have trimmed their price target for LENSAR to $8.50 from $12.50, reflecting updated views on revenue growth, profitability and a lower future P/E, while also pointing to recent upgrades that highlight renewed interest in the stock following the failed Alcon acquisition. Analyst Commentary Recent Street research has focused on the reset expectations for LENSAR following the failed Alcon transaction, as well as the potential runway for the company’s ALLY System.
新しいナラティブ • Mar 31
Recurring Cataract Procedure Revenue And Machine Learning Will Transform This Undervalued Medical Device Story
Catalysts About LENSAR LENSAR develops and commercializes the ALLY Robotic Laser Cataract System for laser assisted cataract surgery. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Mar 19
LNSR: Buy Rating And Post Deal Reset Will Drive Future Reassessment
Analysts have trimmed their fair value estimate for LENSAR from $15.00 to $12.50, pointing to revised assumptions around discount rates, margins, and future P/E, alongside a BTIG upgrade to Buy that highlights past ALLY System adoption and the recent post acquisition selloff as a potential second chance for investors to reassess the story. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the cut in fair value to $12.50 still sits above the current $10 price target.新しいナラティブ • May 10
Global System Placements Will Improve Operating Room Efficiency
Strong system placements and contract pipelines in international markets enhance potential for sustained revenue growth and competitive advantage.分析記事 • Jan 28
Even With A 28% Surge, Cautious Investors Are Not Rewarding LENSAR, Inc.'s (NASDAQ:LNSR) Performance Completely
Despite an already strong run, LENSAR, Inc. ( NASDAQ:LNSR ) shares have been powering on, with a gain of 28% in the...分析記事 • Dec 24
We're Hopeful That LENSAR (NASDAQ:LNSR) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, LENSAR...分析記事 • Oct 24
Market Might Still Lack Some Conviction On LENSAR, Inc. (NASDAQ:LNSR) Even After 28% Share Price Boost
LENSAR, Inc. ( NASDAQ:LNSR ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Sep 12
LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Jul 16
LENSAR, Inc. (NASDAQ:LNSR) Doing What It Can To Lift Shares
With a price-to-sales (or "P/S") ratio of 1.3x LENSAR, Inc. ( NASDAQ:LNSR ) may be sending bullish signals at the...分析記事 • May 01
Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet
Key Insights LENSAR to hold its Annual General Meeting on 7th of May Salary of US$541.1k is part of CEO Nick Curtis's...分析記事 • Feb 22
LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story
LENSAR, Inc. ( NASDAQ:LNSR ) shares have continued their recent momentum with a 33% gain in the last month alone...分析記事 • Jan 24
Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Dec 20
Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy right now...分析記事 • Oct 21
Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Sep 13
Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)
LENSAR, Inc.'s ( NASDAQ:LNSR ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...分析記事 • Mar 21
This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts
One thing we could say about the covering analyst on LENSAR, Inc. ( NASDAQ:LNSR ) - they aren't optimistic, having just...分析記事 • Mar 18
Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Nov 01
Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Aug 08
LENSAR GAAP EPS of -$0.67, revenue of $8M
LENSAR press release (NASDAQ:LNSR): Q2 GAAP EPS of -$0.67. Revenue of $8M (+1.3% Y/Y). Adjusted EBITDA was -$4.3M for the quarter ended June 30, 2022 and -$2.3M for the quarter ended June 30, 2021. As of June 30, 2022, the company had cash and cash equivalents of $25.2M as compared to $31.6M at December 31, 2021. Based on its cash position and operational forecasts, the company believes it has sufficient cash to fund operations into 2024.分析記事 • Mar 23
LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...株主還元
| LNSR | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -7.4% | -1.7% | -2.3% |
| 1Y | -54.2% | -22.4% | 21.2% |
業界別リターン: LNSR過去 1 年間で-22.4 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: LNSRは、過去 1 年間で21.2 % のリターンを上げたUS市場を下回りました。
価格変動
| LNSR volatility | |
|---|---|
| LNSR Average Weekly Movement | 8.1% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: LNSR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: LNSRの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2004 | 150 | Nick Curtis | www.lensar.com |
商業段階の医療機器会社であるLENSAR, Inc.は、米国システム、ヨーロッパ、アジア、韓国、および国際的な白内障治療および既存または手術によって誘発された角膜乱視の管理用レーザーシステムの設計、開発、販売に注力している。同社はLENSAR Laser Systemを提供している。LENSAR Laser Systemは、イメージング、手技計画、デザイン、精度を提供することで、外科医が視覚的結果を得るのを支援するように設計された、さまざまな独自技術を組み込んだものである。また、コンパクトな白内障治療システムであるALLY Robotic Cataract Laser Systemも提供しており、外科医が無菌レーザー支援白内障手術を1つの手術室で行えるように設計されている。LENSAR社は2004年に設立され、フロリダ州オーランドに本社を置いている。
LENSAR, Inc. 基礎のまとめ
| LNSR 基礎統計学 | |
|---|---|
| 時価総額 | US$68.51m |
| 収益（TTM） | US$29.40m |
| 売上高(TTM) | US$57.70m |
2.4x
PER（株価収益率1.2x
P/SレシオLNSR は割高か？
公正価値と評価分析を参照収益と収入
| LNSR 損益計算書（TTM） | |
|---|---|
| 収益 | US$57.70m |
| 売上原価 | US$31.33m |
| 売上総利益 | US$26.38m |
| その他の費用 | -US$3.02m |
| 収益 | US$29.40m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 2.43 |
| グロス・マージン | 45.71% |
| 純利益率 | 50.94% |
| 有利子負債／自己資本比率 | 0% |
LNSR の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/23 19:45 |
| 終値 | 2026/06/23 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
LENSAR, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| Michael Gorman | BTIG |
| Frank Takkinen | Lake Street Capital Markets, LLC |
| Richard Newitter | Leerink Partners LLC |